A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients With Refractory Cutaneous T-Cell Lymphoma.

Next Previous
Trial Profile

A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients With Refractory Cutaneous T-Cell Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2013

At a glance

  • Drugs Forodesine (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 20 Jul 2011 Planned end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Planned number of patients (72) added from M.D. Anderson Cancer Center record.
    • 13 Jun 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top